Leads from Crop Protection against Neglected Diseases







12.8.2014



Why do we need unorthodox approaches to find new tools against Neglected Diseases?

- Most important non-viral infectious diseases worldwide:
- Malaria (*Plasmodium falciparum*)
- Tuberculosis (Mycobacterium tuberculosis)
- Chagas disease (Trypanosoma cruzi)
- Leishmaniasis (Leishmania donovani)
- Sleeping sickness (*Trypanosoma brucei*)
- Buruli ulcer (*Mycobacterium ulcerans*)
- causing 11% of DALYs* and >>1.000.000 deaths/year
- ⇒ UN millennium goal to reduce these "neglected" diseases
- ⇒ Development of new drugs key long term success factor!
- ⇒ <u>But:</u> disappointing progress in providing more drugs

1974-2004: 1535 new drugs (NCEs)







- Hardly addressed by pharma industry in last decades, as deemed commercially unattractive
- Research mainly done by academic sector, supported by PPPs like MMV or DNDi
- No commercial target for BASF, but history in supporting global health projects (Interceptor®, Fendora®, Abate®)
- Sabbatical in 2009 at ETH: could AgChem knowhow help to find innovative solutions?

Why agrochemicals?



- Most important parasitic pathogens are eukaryotes, like e.g. protozoans, worms or helminths
- Agrochemicals are designed to efficiently control eukaryotic organisms, while remaining non-toxic to mammals
- Biocidal Pharma indications (antibiotics, oncology,...) not well suited for serendipitous identification of leads/drugs against eukaryotic neglected disease pathogens
- Since end of the "life science concept" in the late 90's, most agro and pharma companies have separated
- ⇒ As a result very limited crosstalk between agro and pharma

- ⇒ Concepts examined to establish link of agrochemistry and antiparasitic research:
 - Inhibitors of herbicidal pathways against malaria
 - Commercial agrochemicals against protozoan disease pathogens
 - Agrochemically-active natural products against neglected disease pathogens
 - Commercial antiparasitic drugs/published leads against agronomic pests
- So far almost* no examples linking agchem and parasitic disease research!



1st Concept: Herbicidal inhibitors of the non-mevalonate pathway against *P. falciparum*

- Essential pathway in plants
- Plasmodium incorporated a red algae during evolution, resulting in the apicoplast organelle
- Main function of the apicoplast: synthesis of IPP via the non-mevalonate pathway (NMP)
- NMP is not present in mammals

- HTS-screens on several plant-enzymes of NMP at BASF for herbicide lead identification*,**,***
- ⇒ Test of plant HTS hits on *P. falciparum* at SwissTPH (Prof. R. Brun) and further follow-up with groups of Profs. Diederich (ETH), Fischer (Hamburg), Groll (TU Munich)

New concept to generate leads for neglected disease research



Herbicidal NMP-inhibitors with activity against *P. falciparum*


- Hits from HTS-screens:
- Plant target activity:
- Duckweed activity:
- Pf-activity (cell based):

- Optimization:
- Pf-activity (cell based):


- N N N
- 13 μg/ml (IspE)



16 ng/ml




6 ng/ml



2.4 μg/ml (IspD)



69 ng/ml




16 ng/ml



 $0.70 \, \mu g/ml \, (IspD)$



704 ng/ml



499 ng/ml

Identification of potent inhibitors of P. falciparum; different primary targets than NMP?


Herbicidal marine natural product inhibiting IspD and *P. falciparum*




- Pentabromopseudilin natural product from a marine sponge, isolated in 1950s
- Activity on plants with bleaching symptomology published by BASF 1995



- ⇒ Binding in an allosteric pocket next to active site
- ⇒ Unusual halogen-bonding interactions





- ⇒ Very few examples of in vivo active Plasmodium inhibitors in enzyme crystal structures
- ⇒ Even fewer with antiplasmodial natural products!
- Proof of concept for identification of malaria-leads from target based herbicide research!

BASF The Chemical Company


Serine-hydroxymethyl-transferase (SHMT): Pyrazolopyrans

- Pyrazolopyran SHMT inhibitors in vitro-based herbicide project at BASF
 - ⇒ SHMT proposed malaria-target; high sequence homology between plants and *Plasmodium*
 - ⇒ Testing of plant SHMT leads in *P. falciparum* cell based assay at SwissTPH
 - ⇒ Several hits with <100ng/ml; best: **0.7 ng/ml** → better than best standard (Artesunate, 1.6 ng/ml)!



SHMT-inhibitor SHMT (plant) Pf (in blood cell) Cytotox (L6) SHMT (Pf)

IC₅₀: 4 ng/ml IC₅₀: 0.7 ng/ml IC₅₀: 7800 ng/ml IC₅₀: 36 ng/ml



- One of the most active Pf cell-based hits from target based approaches!
- Good cytotox selectivity *Pf* vs. mammalian cells (>5000x)
- Activity on Pf-SHMT and Pv co-crystalstructure (Prof. Chaiyen, Mahidol Univ.)
- In first animal model no significant activity due to ester instability
 - ⇒ Follow-up in Diederich group to improve pharmacokinetics
- Step forward for target-based approach in malaria-research!

PNAS 2014, submitted.



2nd Concept: Commercial agrochemicals as leads against neglected diseases


- Commercial agrochemicals are some of the best studied existing chemicals
- But: No systematic examination of activity against neglected disease pathogens done so far
- ⇒ Test of 700 commercial agrochemicals against major neglected disease pathogens at SwissTPH*
- ⇒ Several interesting leads against all tested pathogens
- ⇒ Especially against malaria several a.i. with nanomolar activity
- ⇒ Some activity also in animal model; but inferior to new pipeline candidates
- ⇒ Further follow-up with analogues with expired IP from BASF compound library

Innovative source of potential new leads against neglected diseases!


Malaria (P. falciparum, P. vivax)




- Resistance against almost all available drugs → high reliance on Artesunate
- Recently candidates with new MOA (GNF156, KAE609) promoted in clinical phases
- 10 agrochemicals with <100 ng/ml in cell-based *P. falciparum* assay
- Hydramethylnon in Pf cell based assay IC₅₀: 23 ng/ml
 - In *P. berghei*-mouse with 4x100 mg/kg oral increase of survival from 3 to 16 days
 - Interesting PK-properties (t1/2: 79/133h), Cmax 10000 ng/ml!
- ⇒ Additional transmission control via insecticidal activity (like Ivermectin)??
- Azoxystrobin in Pf cell based assay IC₅₀: 6 ng/ml
 - In P. berghei-mouse with 4x100 mg/kg s.c. increase of survival from 4 to 13.3 days
 - Excellent activity on liver stage P. berghei (<2.6 ng/ml), comparable to best drugs



Artesunate 2 ng/ml



Hydramethylnon 23 ng/ml



Azoxystrobin 6 ng/ml

- ⇒ Selection of pre-described, patent-expired BASF-strobilurins from 1990's
- ⇒ Strobilurins identified with IC₅₀ << 1 ng/ml; activity at 2x50 mg/kg in mouse; but tight safety margin

Transmission control and/or broad activity on many stages of Pf essential!

Chagas disease (T. cruzi)



- Drugs against Chagas disease with strong side effects: Nifurtimox, Benznidazole
- 10 agrochemicals with <20 ng/ml in cell-based assay
- **Ipconazole** in cell-based *Tc* assay IC₅₀: 1 ng/ml
- Racemic product, therefore likely even higher activity for enantiomers
- In in-vivo mouse models so far only weak activity; pharmacokinetic limitations?
- Related Ravuconazole-prodrug in development by DNDi against Chagas

lpconazole, 1 ng/ml

- ⇒ Comparison of Ipconazole and Ravuconazole on Cyp19 (cause for endocrine side effects) and Cyp51 (*Tc* target enzyme)
- ⇒ Ipconazole more active on Cyp51, 300x-selectivity window; Ravuconazole only 9x!
- ⇒ Clinical studies from Ravuconazole prodrug not successful due to high recrudescence
- ⇒ Deprioritization of Cyp51 inhibitors as Chagas drug candidates

> Ipconazole highly potent cell-based inhibitor, but target likely not suited for cure



Leishmaniasis (*L. donovani*) Sleeping sickness (*T. brucei*)

- Current treatments against Leishmaniasis with severe side effects: Miltefosine; Antimony complexes
- Most interesting hit **Zoxamide** (IC₅₀ **84 ng/ml**)
- Access to animal models difficult
- Further selected analogues in testing

- Current treatments for sleeping sickness: Eflornitin (expensive; dose 400 mg/kg/d!); Arsenic derivatives
- Most interesting hit also **Zoxamide** (IC₅₀ **2 ng/ml**)
- Zoxamide (LD₅₀>2000 mg/kg) in mouse model at 4x50 mg/kg with some activity (no parasites after 7 days, but recurrence after 10 days)
- No improved activity with different dosing
- ⇒ Zoxamide rapidly metabolized in vivo

Zoxamide most interesting candidate, but likely too labile for curative action

Buruli Ulcer (M. ulcerans)



■ Only medication Rifampicin+Streptomycin (toxic in chronic application; IC₅₀ 300 ng/ml)

- NH₂ HOHOH
- Streptomycin, 300 ng/ml
- CI N
- Viniconazole, 800 ng/ml
- Fluazinam, 300 ng/ml
 - N N
- MIC (IC₉₀) 31 ng/ml!

- First interesting hit: **Viniconazole** (= Croconazole, fungicidal drug)
 - Cell based M. ulcerans assay IC₅₀ 800 ng/ml*
 - All other 48 commercial azole agrochemicals and drugs inactive in assay
 - Could also treat opportunistic fungal infections; inhibition of Mycolactone synthesis??
- Most potent hit from screen: Fluazinam
 - Cell based *M. ulcerans* IC_{50} **300 ng/ml** (LD₅₀ >2000 mg/kg)
 - Likely difficult to use as drug due to short half-life ($t_{1/2}$: 1.3 h)
- Other hits from published Mt screen also highly active on Mu
- ⇒ Further follow-up supported using BASF compound base

Further studies with Viniconazole and new hits ongoing




3rd Concept: Agrochemically-active natural products against protozoans

Several published natural products with agrochemical activity tested on neglected disease pathogens



Pseudilin (H) 700 ng/ml (*Pf*)




Mycophenolicacid (H) 1613 ng/ml (*Pf*)




Tentoxin (H) 4973 ng/ml (*Pf*)

Strobilurin A (F) 336 ng/ml (*Pf*)

Shikonin (F) 14 ng/ml (*T. brucei*)



Mollisin (F) 38 ng/ml (*T. brucei*)



Thiolutin (F) 19 ng/ml (*T. brucei*)

Several natural products with promising activity against protozoans identified!



4th Concept: Herbicidal activity of antiparasitic drugs and HTS-hits

Purchase of 126 commercial antiparasitic drugs and test in herbicide screening:


Fosmidomycin inhibitor of non-mevalonate pathway (DXS)

Artemisinin (perturbing redox homeostasis)

Sulfamethoxazole inhibitor of folate synthesis (dihydropteroate synthetase)

Clindamycine inhibitor of protein biosynthesis (50s rRNA inhibitor)

Carnidazole (DNA biosynthesis in anaerobic cells)



Several herbicidal drugs identified; potential leads with target, SAR and tox-evaluation!



Herbicidal activity of hits from published antimalarial screens

Commercial hits from HTS-runs against Pf have been published by e.g. GSK, Novartis,...

 $Pf IC_{50}$


Benzochinon GNF-Pf-3600 24 nM

Nitropyrimidon CHEMBL598903 358 nM

Benzpyrimidon CHEMBL585425 1016 nM

Triazolopyrimidin CHEMBL475813 79 nM

Salicylamide TCMDC-124051 1141 nM





Insecticidal activity of hits from published antimalarial screens

		Structure	sucking	sucking	chewing
	Pf IC ₅₀	2500ppm; % control	protective	curative	curative
Imidazolium CHEMBL603013	459 nM	Br. C	63	25	100
Urea CHEMBL10835	1160 nM		6	69	100
Coumaron CHEMBL532382	265 nM	OH OCH3	0	25	100
Benzamide CHEMBL601789	1935 nM		0	0	81
Pyridonimin CHEMBL568092	189 nM	H N OH,	63	0	19



Fungicidal activity of hits from published antimalarial screens

ر م ا

		Ascomycota Oomycetes Basidomycota
	Pf IC ₅₀	100ppm, % infection curative protective protective
Imidazolium CHEMBL603519	319 nM	25 50 54
Pyridinium CHEMBL1482585	2936 nM	H ₃ C CH ₅ 33 75 50
Pyrimidine CHEMBL528809	1017 nM	83 17 67
Indol CHEMBL285157	1045 nM	92 17 71
Carbazole CHEMBL 537336	97 nM	75 0 100

Conclusions



- Agrochemical target based research can provide highly potent antimalarial leads
- Commercial agrochemicals can provide interesting leads for neglected disease research
- Natural products identified in agrochemical screens can show high activities also against human pathogens
- Compounds active against human pathogens can also show high activity against agronomic pests
- ⇒ Based on this project many interesting new leads for neglected disease- as well as for agrochemical research could be identified
- ⇒ Win-win link for agrochemical- and neglected disease-research!

Proof of concept, that linking AgChem- and Neglected Disease-research makes sense!

Acknowledgements



ETH, Zürich:

- Prof. F. Diederich
- M. Seet
- Prof. G. Schneider

SwissTPH, Basel:

- Prof. R. Brun
- Prof. P. Mäser
- M. Rottmann
- M. Kaiser
- Prof. G. Pluschke
- N. Scherr

University of Hamburg:

- Prof. M. Fischer
- B. Illarionov
- Prof. A. Bacher

TU München:

- Prof. M. Groll
- A. Kunfermann

Mahidol University, Bangkok:

- Prof. P. Chaiyen
- U. Leartsakulpanich
- P. Chitnumsub

BASF SE, Ludwigshafen:

- A. Kreimeyer
- H. Lauke
- T. Mietzner





Non-mevalonate pathway



Folate cycle

